Sign inCreate account

Report workspace tools

NCT01061099COMPLETEDanonymous

A Pilot Study to Assess the Safety and Feasibility of Repeated Infusions of Mesenchymal Stromal Cells (MSC) in Children With Osteogenesis Imperfecta

Sponsor

Source record

Nationwide Children's Hospital

Phase

Source record

PHASE1

Modality

AI-normalized

cell therapy

Target

AI-normalized

Mesenchymal Stromal Cells

Indication / condition

AI-normalized

Osteogenesis Imperfecta Type II

Intervention

Source record

Mesenchymal Stromal Cells

Source & freshness

Source record

NCT ID

NCT01061099

Original source

ClinicalTrials.gov

Source last updated

Apr 24, 2015

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01061099

Title

A Pilot Study to Assess the Safety and Feasibility of Repeated Infusions of Mesenchymal Stromal Cells (MSC) in Children With Osteogenesis Imperfecta

Sponsor

Nationwide Children's Hospital

Status

COMPLETED

Phase

PHASE1

Condition raw

Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III

Condition normalized

Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III

Modality raw

cell therapy

Modality normalized

cell therapy

Target raw

Mesenchymal Stromal Cells

Target normalized

Mesenchymal Stromal Cells

Interventions

Mesenchymal Stromal Cells

Public preview

Source record

This is a study to evaluate the safety and effectiveness of repeated Mesenchymal Stromal Cells (MSC) infusions to patients with Type II or III osteogenesis imperfecta (OI).

Participants will receive MSC infusions approximately every 4 months to complete a total of 6 infusions over 20 months. Participants will be followed for 4 months post their last MSC infusion.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Pilot Study to Assess the Safety and Feasibility of Repeated Infusions of Mesenchymal Stromal Cells (MSC) in Children With Osteogenesis Imperfecta

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01061099

Status

COMPLETED

Phase

PHASE1

Sponsor

Nationwide Children's Hospital

Executive brief

Investment-Ready Snapshot

This is a study to evaluate the safety and effectiveness of repeated Mesenchymal Stromal Cells (MSC) infusions to patients with Type II or III osteogenesis imperfecta (OI). Participants will receive MSC infusions approximately every 4 months to complete a total of 6 infusions over 20 months. Participants will be followed for 4 months post their last MSC infusion.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 24, 2015
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01061099

Indication

Osteogenesis Imperfecta Type II

Modality

cell therapy

Target

Mesenchymal Stromal Cells

Intervention

Mesenchymal Stromal Cells

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.